FindMyRecallSubscribe
Class I: serious health riskOngoing

Novartis Pharmaceuticals SANDIMMUNE Oral Solution Recall

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx…

Novartis Pharmaceuticals Corporation · East Hanover, NJ

Risk level
Class I
Reported by FDA
Dec 13, 2023
Recall ID
D-0144-2024
Check your lot numberHow we source this data

Summary

Novartis Pharmaceuticals recalled SANDIMMUNE Oral Solution starting Nov 22, 2023. The FDA classified it as Class I (serious health risk) and published enforcement report D-0144-2024 on Dec 13, 2023. Reason: Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals. Status: Ongoing.

Why it was recalled

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Product description

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. NDC 0078-0110-22

Lot numbers, UPCs & expiration codes

Lot #: FX001500, FX001582, Exp. 09/30/2024

Where it was sold

Nationwide within the United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0144-2024
Classification
Class I
Status
Ongoing
Recall initiated
Nov 22, 2023
FDA report date
Dec 13, 2023
Quantity
6,997 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Novartis Pharmaceuticals Corporation

Original FDA data

Every field from FDA enforcement report D-0144-2024, exactly as published.

Show all FDA fields
City
East Hanover
State
NJ
Status
Ongoing
Country
United States
Event ID
93464
Address
1 Health Plz
Code information
Lot #: FX001500, FX001582, Exp. 09/30/2024
Postal code
07936-1016
Report date
Dec 13, 2023
Product type
Drugs
Recall number
D-0144-2024
Classification
Class I
Recalling firm
Novartis Pharmaceuticals Corporation
Product quantity
6,997 bottles
Reason for recall
Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals
Voluntary / mandated
Voluntary: Firm initiated
Product description
SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. NDC 0078-0110-22
Distribution pattern
Nationwide within the United States
Recall initiation date
Nov 22, 2023
Initial firm notification
Letter
Center classification date
Dec 7, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0144-2024, published Dec 13, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls